Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.65 |
| ▸ | CNR1 | P21554 | 7/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520138 | 0.80 | CNR2 (0.77) | CNR2CNR1PTGS1PTGS2 | |
| SCHEMBL2773002 | 0.80 | CNR2 (0.73) | CNR2CNR1CA1CA2PTGS1 | |
| SCHEMBL2772874 | 0.79 | CNR2 (1.00) | CNR2CNR1CA1CA2 | |
| Hydrochloric Acid SCHEMBL6524573 | 0.78 | CNR2 (0.98) | CNR2CNR1CA1CA2 | |
| SCHEMBL4938480 | 0.70 | CNR2 (0.62) | CNR2CNR1CA1CA2PTGS1 | |
| SCHEMBL6526786 | 0.69 | CNR2 (0.61) | CNR2CNR1PTGS1PTGS2 | |
| SCHEMBL2774400 | 0.68 | CNR2 (1.00) | CNR2CNR1CA1CA2PTGS1 | |
| Hydrochloric Acid SCHEMBL6521926 | 0.67 | CNR2 (0.98) | CNR2CNR1CA1CA2PTGS1 | |
| SCHEMBL2774825 | 0.66 | CNR2 (0.78) | CNR2CNR1CA1CA2PTGS1 | |
| SCHEMBL9456821 | 0.65 | CNR2 (0.49) | CNR2CNR1CA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2201007-A1 | CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009071753-A1 | CANNABINOID RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059970-A1 | 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885CNR1 1/4885CA1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.